Skip to main content
Fig.4 | Journal of Nanobiotechnology

Fig.4

From: Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery

Fig.4

Nasal instillation of MSNs-Bi reduced intestinal inflammation and shaped gut microbiota. a Schematic diagram of MSNs-Bi treatment of 4 month-old APP/PS1 mice; n = 3. b Representative hematoxylin and eosin-stained images of colon tissues from APP/PS1 mice after treatment with PBS, MSNs, Bifidobacterium, and MSNs-Bi; Bi refers to Bifidobacterium, scale bars = 100 µm. c Crypt length of colon tissues from APP/PS1 mice treated with PBS, MSN, Bifidobacterium, and MSNs-Bi. d SCFAs levels in feces of APP/PS1 mice treated with PBS, MSNs, MSNs-Bi, and Bifidobacterium. e Composition of the gut microbiome of APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi. The Y-axis represents the relative abundance of genus-level gut microbial taxa. f Bifidobacterium abundance (log2 transformed) in the gut microbiome of C57BL/6J mice (WT) and APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi. g Representative images of ThioS staining of the gut of APP/PS1 mice after treatment with PBS, MSNs, Bifidobacterium, and MSNs-Bi; scale bars = 100 µm. h42 levels in the stomach, duodenum, jejunum, ileum, cecum, and colon of APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi

Back to article page